Capital Architecture &
Institutional Investor Relations.
DeepSensi PBC unites the world's highest-performing clinical AI diagnostic engine with a highly scalable Decentralized Clinical Trial (DCT) architecture. By shifting the clinical paradigm from traditional high-burn CRO models to software-driven patient telemetry, we have set a new standard for global evidence generation.
EXECUTIVE STRATEGY // THE THREE STRUCTURAL MOATS
Three Structural Advantages No One Else Combines
Conventional healthcare AI companies build thin wrappers subject to rapid commoditization and crushing regulatory burdens. DeepSensi operates on a fundamentally divergent mathematical, legal, and commercial paradigm.
Deterministic Cognitive Engine
Single-prompt models hallucinate and fail in complex multi-system medicine. DeepSensi executes a multi-agent Consilium with ≥23 deterministic safety barriers and the LIMBO protocol (formal refusal to guess under high uncertainty).
The Product Is the Evidence Engine
Conventional sponsors build a new recruitment machine for every trial. DeepSensi does not: the Precision Suite is in daily use by families and clinics, and the RESOLVE™ registries grow out of that installed base, participation always free, under independent ethics review. The economics of the model are documented in the data room.
Zero Cloud Egress & Enterprise Governance
Enterprise hospitals and sovereign healthcare jurisdictions demand uncompromising data security. DeepSensi is deployable on air-gapped on-premise nodes with zero cloud egress, satisfying the most stringent global cybersecurity criteria for sovereign medical deployments without exposing sensitive internal metrics.
CLINICAL TRIAL ASSETS // DUAL COMPLEMENTARY VALIDATION ENGINES
The Dual Trial Engine: RESOLVE™ and SILENT-DS™
Two complementary pre-registered clinical protocols providing total regulatory and commercial market coverage across outpatient chronic registries and acute inpatient emergency admissions.
The 9 RESOLVE™ DCT Registries
Target: N = 90,000 subjects across 9 disease pillars (Epilepsy, Neuro-Immune, Autoimmunity, POTS/Cardio, Metabolic, Rare/Orphan, Oncology, Endometriosis, TRD Psychiatry).
Mechanism: Decentralized, home-based biomarker telemetry (OAT, microbiome, metabolomics) paired with the optional Precision Suite™ protocol ($790 case intake & 12-month longitudinal tracking access).
Registration: Open Science Framework pre-registration (DOI: 10.17605/OSF.IO/VPS9D); ClinicalTrials.gov (PRS in progress).
SILENT-DS™ Diagnostic Accuracy Study
Target: N = 10,000 consecutive adult internal-medicine admissions at five or more U.S. hospitals.
Mechanism: Observer-blinded shadow evaluation running in silent-mode on live EHR feeds. Tests non-inferiority and then superiority of top-3 diagnostic concordance against the working diagnoses of the admission note, under blinded adjudication.
Registration: OSF pre-registration in preparation (Protocol ID: DS-CLIN-2026-SILENT-DS) and ClinicalTrials.gov (PRS submission in progress).
GLOBAL OPERATING MODEL // NATIONAL OPERATING COMPANIES
One licensed operator per country.
DeepSensi expands through national operating companies, one per market. Each national arm holds the exclusive territorial licence to the Cognitive Engine and the DeepSensi brand and conducts all in-country business: deployments to hospitals and health systems, public-sector and payer contracting, clinical operations for the RESOLVE™ registries, the national physician network and local regulatory compliance.
A small number of partners join each national company, each with capital and a measurable contribution. Terms are not published: the National Partner Program opens in stages, after an introductory conversation, in the partner data room.
- The national company
- Holds the exclusive, durable territorial licence. It sells, deploys, contracts and operates in its country; all in-country business runs through it.
- DeepSensi
- Keeps the platform and the entire intellectual property. Certification to the DeepSensi Standard (DSS) and a common pricing corridor are conditions of every licence: one architecture in every country.
- National partners
- Bring regulatory and structural reach, market reach, or funding, and earn their position against delivery, under agreed milestones.
INVESTOR DATA ROOM (RESTRICTED ACCESS) // ACCESS BY VERIFICATION
How data room access works
Financial models, the cap table and the complete regulatory dockets are not published. They are shared only with eligible investors and national partners, after review, one person, one access code.
Request
Tell us who you are, in the form below. Investors and prospective national partners use the same form.
Verification
We confirm your institution and your accredited or qualified investor status, and a confidentiality agreement is signed. No material moves before that.
Personal access
Access to materials is granted at the Company's discretion after review. When it is granted, you receive a personal access code; sessions are time-limited, and every document opening is logged to that code.
INVESTOR RELATIONS // INVESTOR DATA ROOM (RESTRICTED ACCESS)
Investor relations
DeepSensi Public Benefit Corporation shares investor materials only with eligible investors. Please tell us about yourself.
This page provides general information about DeepSensi Public Benefit Corporation. It is not an offer to sell or a solicitation of an offer to buy any security.
